

REPROGRAMMING OF T CELLS TO NATURAL KILLER-LIKE CELLS UPON BCL11B DELETION

A Dissertation submitted in fulfilment of the
requirements for the degree of Doctor of Philosophy

By Peng Li



University of Cambridge, Queens' College
The Wellcome Trust Sanger Institute

September 2010

DECLARATION

I hereby declare that this dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration, except where specially indicated in the text. None of the material presented herein has been submitted previously for the purpose of obtaining another degree. I confirm that this thesis does not exceed 300 single sided pages of double spaced text, or 60,000 words.

Peng Li

For always being there, Dad,

Mum, and Wife

ACKNOWLEDGEMENT

First and foremost, I would like to express my deepest appreciation to my PhD supervisor, Dr Pentao Liu, for his patience and guidance in the projects. It was great to have such an enthusiastic mentor who is always full of creative ideas! I thank him for the challenging projects and the stimulating discussions we had in the lab. I would also like to thank Pentao's lab members, past and present, for their advice, help, and encouragement. Special mention goes to Dr Shannon Burke and Dr Mariaestela Ortiz. Dr Shannon Burke taught me the basis knowledge of immunology, gave me enormous help in experiments, and improved my thesis. In particular, he helped me conduct the killing assays and lymphocyte transfer experiments in this thesis. Dr Mariaestela Ortiz taught me the basic knowledge of haematology and cell cultures and read my thesis. I thank Miss Juexuan Wang for providing a precious Bcl11b reporter mouse used in this thesis. I also thank Dr Song-Choon Lee for instructing me for my molecular biology experiments, Dr Su-Kit Chew, Dr Lia Campos, and Dr Dong Lu for the advice and help they have given me. I thank Yong Yu for taking care of my cells when I wrote my thesis.

Next, I would like to thank the members of the RSF for their excellent technical help in taking care of my mice. I also would like to thank Dr Bee Ling Ng and William Cheng for their help in flow sorting and FACS analysis. Additionally, I thank Dr. David Goulding for taking transmission electronic microscopy images in this thesis.

I was extremely fortunate to have external collaboration with Dr Francesco Colucci and Dr Shannon Burke on natural killer cell studies when they were at Babraham Institute. Their invaluable advice on my project and professional help with my experiments made everything went smoothly. I thank Dr. Xiongfeng Chen from

National Cancer Institute for the microarray analysis in this thesis. I also want to thank Bertie Gottgens and Nicola Wilson from Cambridge Institute for Medical Research for teaching me ChIP assays.

I would love to thank Dr Brian Huntly, my secondary PhD supervisor, who gave me invaluable advice and help on my projects. I also would like to thank my thesis committee, Prof Allan Bradley, Prof Gordon Dougan, and Dr Christine Watson for our valuable meetings and thoughtful suggestions.

Last but not least, I would like to thank my parents Hanguo Li and Yuzhen Liu for their unconditional love and support throughout twenty years of my studies. I would also like to thank my wife, Yao Yao, for her understanding, encouragement, and for always being there to support me in these four years.

REPROGRAMMING OF T CELLS TO NATURAL KILLER-LIKE CELLS UPON BCL11B DELETION

Peng Li

T cells develop in the thymus and play critical roles in immunity. In mice, the transcription factor Bcl11b is required for fetal thymocyte development and for double-positive thymocyte selection. Using a *Bcl11b-tdTomato* knock-in reporter mouse, I found that *Bcl11b* was T-cell-restricted, and was expressed from very early thymocytes to all mature T cells.

To study the functions of Bcl11b in adult T cells, I used a *Bcl11b* conditional knockout mouse strain and demonstrated that Bcl11b was indispensable for early T cell development and for the maintenance of T cell identity. Deletion of Bcl11b caused early T cells to lose their T cell potential and differentiate to natural killer (NK)-like cells in T cell cultures. Similarly, acute loss of Bcl11b in committed and mature T cells resulted in the reprogramming from T cells to induced-T-to-natural killer (ITNK) cells in a cell-autonomous manner. ITNKs derived in vitro and in vivo exhibited many NK cell features, such as expression of NK cell surface markers and lysis of NK tumor targets. In addition, ITNKs derived in vivo were able to prevent the outgrowth of tumour cells in a mouse model.

The gene expression profiles of ITNKs were also similar to that of regular NK cells, and not their parental T cells. ITNKs upregulated NK cell-associated genes while downregulated T cell genes, suggesting that Bcl11b might regulate the T-versus-NK cell fate choice. Furthermore, results from chromatin immunoprecipitation assays confirmed that the canonical Notch signaling directly regulated Bcl11b transcription level.

In summary, I showed that Bcl11b is essential for T cell development and is currently the only known transcription factor critical for the maintenance of T cell identity. Finally, it is believed that human ITNPs may potentially be exploited for therapeutic use in cancer treatments.

LIST OF ABBREVIATIONS

β -gal	β -galactosidase
ACT	Adoptive cell transfer
AGM	Aorta-gonad-mesonephros
AIDS	Acquired immune deficiency syndrome
BAC	Bacteria artificial chromosome
BCA	BioCinchominic Acid
Bcl	B-cell lymphoma/leukaemia
BCR	B cell receptor
BM	Bone marrow
BSA	Bovine serum albumin
ChIP	Chromatin immunoprecipitation
CKO	Conditional knockout
CLP	Common lymphoid progenitors
CMP	Common myeloid progenitors
COUP-TF	Chicken ovalbumin upstream promoter transcription factor
CRAC	Calcium release-activated Ca^{2+}
CTIP	COUP-TF interacting protein
CTLs	Cytotoxic T lymphocytes
DAG	Diacylglycerol
DMSO	Dimethyl sulfoxide
DN	Double negative ($\text{CD4}^- \text{CD8}^-$)
Dox	Doxycyclin
DP	Double positive ($\text{CD4}^+ \text{CD8}^+$)
dpc	Days post-coitum
eGFP	Enhanced green fluorescent protein
ENU	N-ethyl-N-nitrosourea
ER	Estrogen receptor
ES	Embryonic stem
ETP	Early T cell precursors
FACS	Fluorescent-activated cell sorting
FCS	Fetal calf serum
FDG	Fluorescein di- β -D-galactopyranoside
Flt	Fms-like tyrosine kinase receptor
G-CSF	Granulocyte colony-stimulating factor
GM-CSF	Granulocyte/macrophage colony-stimulating factor
GMP	Granulocyte macrophage progenitors
HD	Huntington's disease
HDAC	Histone deacetylase
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigens
HRP	Horseradish peroxidase
HSC	Hematopoietic stem cell
IFN	Interferon
IHC	Immunohistochemistry
IL	Interleukin
IRES	Internal ribosome entry site
iPS	Induced pluripotent stem
IP3	Inositol trisphosphate

ISP	Immature single-positive
ITAMs	Immunoreceptor tyrosine-based activation motifs
ITK	Inducible T cell kinase
ITNK	Induced T-to-natural-killer
LAK	Lymphokine-activated killer
LCK	Lymphocyte protein-tyrosine kinase
Lin	Lineage
M-CSF	Macrophage colony-stimulating factor
MEP	Megakaryocyte erythroid progenitors
MHC	Major histocompatibility complex
MTA	Metastasis-associated proteins
NCoR	Nuclear receptor co-repressor
NICD	Notch intracellular domain
NK cells	Natural killer cells
NKP	Natural killer cell precursor
NKT cells	Natural killer T cells
NSC	Neural stem cells
NuRD	Nucleosome remodeling and histone deacetylase
NZB	New Zealand black
OHT	4-hydroxytamoxifen
PAGE	Polyacrylamide gel electrophoresis
PB	PiggyBac
PI	Phosphatidylinositol
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC γ 1	Phosphorylation of phospholipase C γ 1
polyA	Polyadenylation signal
pre-BCR	pre-B cell receptors
Pre-TCR	Pre-T cell receptors
qRT-PCR	Quantitative real-time reverse transcription PCR
RNAi	RNA interference
RT	Room temperature
SCF	Stem cell factor
SCID	Severe combined immune deficiency
SIRT1	Sirtuin 1
SMRT	Silencing mediator for retinoid and thyroid hormone receptor
SP	Single positive
T-ALL	T-cell adult leukemia/lymphoma
TCR	T cell receptor
tdTomato	Tandem dimmer Tomato
Tet	Tetracycline
TetR	Tet repressor protein
TGF	Transforming growth factor
Th2	T-helper-2
TIL	Tumour-infiltrating lymphocyte
TNF	Tumour necrosis factor
TNKP	T/NK progenitor
TRE	Tetracycline response element
tTA	Tetracycline-controlled transactivator
UTR	Untranslated region
X-gal	5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside

Zap-70
ZFN

Z-chain associated protein kinase
Zinc finger nuclease

TABLE OF CONTENT

Chapter 1	7
INTRODUCTION	
1.1. Mouse as a genetic tool.....	7
<i>1.1.1. A brief history.....</i>	<i>7</i>
<i>1.1.2. Genetic manipulation of the mouse genome.....</i>	<i>7</i>
<i>1.1.3. Using the mouse to study immunity.....</i>	<i>9</i>
1.2. Conditional knockout (CKO) mice.....	10
<i>1.2.1. CKO technology and its application</i>	<i>10</i>
<i>1.2.2. Inducible Cre systems.....</i>	<i>12</i>
1.3. Lymphopoiesis.....	13
<i>1.3.1. Haematopoiesis</i>	<i>13</i>
<i>1.3.2. B cell development.....</i>	<i>14</i>
<i>1.3.3. T cell development.....</i>	<i>15</i>
<i>1.3.4. TCR signaling.....</i>	<i>17</i>
<i>1.3.5. NK cell development.....</i>	<i>18</i>
<i>1.3.6. NKT cell development.....</i>	<i>19</i>
1.4. Function of Bcl11b	20
<i>1.4.1. Bcl11a.....</i>	<i>20</i>
<i>1.4.2. Bcl11b in leukemia</i>	<i>21</i>
<i>1.4.3. Bcl11b in early T cell development</i>	<i>22</i>
<i>1.4.4. Bcl11b in mature T cells.....</i>	<i>23</i>
<i>1.4.5. Bcl11b in other tissues</i>	<i>24</i>
<i>1.4.6. Binding sites of Bcl11b.....</i>	<i>25</i>

1.5. Thesis projects	26
Chapter 2	28
MATERIAL AND METHODS	28
2.1. Mouse techniques	28
2.1.1. <i>Animal husbandry</i>	28
2.1.2. <i>Tamoxifen administration</i>	29
2.1.3. <i>Intravenous tail vein injection</i>	29
2.2. DNA methods	29
2.2.1. <i>Extraction of DNA from primary cells</i>	29
2.2.2. <i>Extraction of DNA from tissues</i>	30
2.2.3. <i>Genotyping PCR</i>	30
2.2.4. <i>TCR rearrangement PCR</i>	30
2.3. RNA methods	31
2.3.1. <i>Extraction of total RNA from cells</i>	31
2.3.2. <i>First strand cDNA synthesis</i>	32
2.3.3. <i>RT-PCR</i>	32
2.3.4. <i>qRT-PCR</i>	33
2.3.5. <i>Taqman</i>	33
2.3.6. <i>SYBR Green</i>	33
2.4. Protein methods	34
2.4.1. <i>Protein extraction</i>	34
2.4.2. <i>BioCinchoninic Acid (BCA) assay</i>	34
2.4.3. <i>SDS-PAGE</i>	34
2.4.4. <i>Immunoblotting</i>	35
2.4.5. <i>Primary antibody incubation</i>	35

2.4.6. <i>Secondary antibody incubation and detection</i>	35
2.5. Flow cytometry and cell sorting	36
2.5.1. <i>Single cell suspension</i>	36
2.5.2. <i>DN thymocytes enrichment</i>	36
2.5.3. <i>Staining of cell-surface antigens</i>	37
2.5.4. <i>CD1d stain</i>	37
2.5.5. <i>Staining for intracellular antigens</i>	38
2.6. Cell culturing	38
2.6.1. <i>Culture of OP9 and OP9-DL1 stromal cells</i>	38
2.6.2. <i>Culture of T cells</i>	39
2.6.3. <i>Culture of myeloid cells</i>	39
2.6.4. <i>Culture of B cells</i>	39
2.6.5. <i>Culture of NK cells</i>	40
2.6.6. <i>Culture of Lymphokine-activated killer (LAK) cells</i>	40
2.6.7. <i>Culture of tumour cell lines</i>	40
2.6.8. <i>Activation of unprimed T cells</i>	41
2.6.9. <i>OHT treatment in vitro</i>	41
2.7. Gene expression analysis	41
2.8. Chromatin immunoprecipitation	41
2.9. Tumour killing assays	42
2.10. Calcium flux	42
Chapter 3	43

BCL11B EXPRESSION IN HEMATOPOIETIC LIENAGES	43
3.1. Introduction.....	43
3.1.1. <i>Current knowledge of Bcl11b expression patterns</i>	43

3.1.2. <i>Reporter Molecules in Genetically Engineered Mice</i>	43
3.1.3. <i>Purposes of this chapter</i>	44
3.2. Results.....	45
3.2.1. <i>Bcl11b expression in thymocytes</i>	45
3.2.2. <i>Bcl11b expression in mature T cells</i>	46
3.2.3. <i>Bcl11b expression in other hematopoietic cells</i>	47
3.3. Discussion.....	47
3.3.1. <i>Bcl11b is T-cell specific</i>	48
3.3.2. <i>Advantages and pitfalls of Bcl11b-<i>tdTomato</i> knock-in mice</i>	48
Chapter 4	50

BCL11B IS REQUIRED FOR EARLY T CELL DEVELOPMENT AND MAINTAINANCE OF T CELL IDENTITY	
.....	50
4.1. Introduction.....	50
4.1.1. <i>Notch signaling in T cell development</i>	50
4.1.2. <i>Key transcription factors in T cells</i>	51
4.1.3. <i>NK cell-associated genes</i>	52
4.1.4. <i>Purposes of this chapter</i>	54
4.2. Results.....	54
4.2.1. <i>Bcl11b transcription regulation in T cells</i>	54
4.2.2. <i>Bcl11b is required for early T cell development</i>	55
4.2.3. <i>Bcl11b is required for committed T cells</i>	57
4.2.4. <i>Reprogramming efficiency from T cells to iTNKS upon Bcl11b ablation</i>	59

4.2.5. <i>Bcl11b</i> is required in mature T cells	60
4.2.6. ITNKS detected in Tamoxifen-treated flox/flox mice.....	61
4.2.7. Reprogramming from T cells to ITNKS in vivo	63
4.2.8. <i>Bcl11b</i> is positively regulated by Notch signaling	64
4.3. Discussion.....	65
4.3.1. Deletion of <i>Bcl11b</i> using different Cre systems	66
4.3.2. Possible factors affecting reprogramming efficiency.....	67
4.3.3. “Unconventional NKT cells” in wild type mice.....	69
4.3.4. Dynamic balance of ITNKS in vivo.....	69
Chapter 5.....	71
CHARACTERIZATION AND APPLICATION OF ITNKS 71	
5.1. Introduction.....	71
5.1.1. Cancer immunotherapy	71
5.1.2. Purposes of this chapter.....	73
5.2. Results.....	73
5.2.1. Gene expression profile in ITNKS	73
5.2.2. Characterization of ITNKS derived in vitro	75
5.2.3. Characterization of ITNKS derived in vivo	76
5.2.4. Killing ability of ITNK derived in vitro	78
5.2.5. Killing ability of ITNK derived in vivo.....	78
5.2.6. ITNKS prevent tumour expansion in vivo	79
5.3. Discussion.....	80
5.3.1. Potential targets of <i>Bcl11b</i>	80
5.3.2. Differences between ITNKS derived in vitro and in vivo.....	81
5.3.3. Application of ITNKS for tumor killing	82

Chapter 6.....	84
GENERAL DISCUSSION..... 84	
6.1. Summary	84
6.1.1. <i>Bcl11b expression in T cells</i>	84
6.1.2. <i>Bcl11b functions in early T cells</i>	85
6.1.3. <i>Bcl11b functions in committed and mature T cells</i>	86
6.1.4. <i>Bcl11b transcription regulatory networks</i>	88
6.1.5. <i>Potentials of ITNKs in immunotherapy</i>	89
6.2. Significance	89
6.2.1. <i>Novel roles of Bcl11b in the maintenance of T cell identity</i>	89
6.2.2. <i>Clinical potential of ITNKs</i>	90
6.3. Future experiments	90
6.3.1. <i>Upstream genes of Bcl11b</i>	91
6.3.2. <i>Downstream genes of Bcl11b</i>	93
6.3.3. <i>Overexpression of Bcl11b in ITNKs and NK cells</i>	94
6.3.4. <i>Reprogramming human T cells to ITNKs</i>	94
6.3.5. <i>Testing the tumor-killing ability of human ITNKs</i>	95
6.4. Conclusions.....	96
REFERENCES 97	